10 Biotechnology Stocks to Sell Now

CVM, EPRS, OHRP, TSRX, VICL, TENX, SGYP, VSTM, CLDX, TRVN slump in weekly rankings

The ratings of 10 biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, CEL-SCI Corporation (CVM) falls to a D (“sell”), worse than last week’s grade of C (“hold”). CEL-SCI is developing new immune system based treatments for cancer and infectious diseases. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, CVM also gets F’s. To get an in-depth look at CVM, get Portfolio Grader’s complete analysis of CVM stock.

EPIRUS Biopharmaceuticals, Inc. (EPRS) experiences a ratings drop this week, going from last week’s C to a D. The stock also gets an F in Earnings Revisions. For more information, get Portfolio Grader’s complete analysis of EPRS stock.

The rating of Ohr Pharmaceutical Inc (OHRP) declines this week from a C to a D. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. To get an in-depth look at OHRP, get Portfolio Grader’s complete analysis of OHRP stock.

Trius Therapeutics, Inc. (TSRX) experiences a ratings drop this week, going from last week’s C to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.

The rating of Vical Incorporated (VICL) declines this week from a C to a D. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at VICL, get Portfolio Grader’s complete analysis of VICL stock.

Tenax Therapeutics, Inc. (TENX) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). The stock receives F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TENX stock.

Slipping from a D to an F rating, Synergy Pharmaceuticals, Inc. (SGYP) takes a hit this week. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of July 8, 2015, 20.1% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. To get an in-depth look at SGYP, get Portfolio Grader’s complete analysis of SGYP stock.

Verastem, Inc. (VSTM) earns an F this week, moving down from last week’s grade of D. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. As of July 8, 2015, 11.4% of outstanding Verastem, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VSTM stock.

This is a rough week for Celldex Therapeutics, Inc. (CLDX). The company’s rating falls to D from the previous week’s C. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also rates an F in Equity. As of July 8, 2015, 16.5% of outstanding Celldex Therapeutics, Inc. shares were held short. To get an in-depth look at CLDX, get Portfolio Grader’s complete analysis of CLDX stock.

This week, Trevena, Inc.’s (TRVN) rating worsens to a D from the company’s C rating a week ago. The stock gets F’s in Equity and Cash Flow. Shares of the stock have been trading at an exceptionally rapid pace, up fourfold from the week prior. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/07/10-biotechnology-stocks-to-sell-now-cvm-eprs-ohrp-9/.

©2019 InvestorPlace Media, LLC